Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone |
| |
Authors: | Andréen Lotta Sundström-Poromaa Inger Bixo Marie Andersson Agneta Nyberg Sigrid Bäckström Torbjörn |
| |
Affiliation: | 1. Department of Pharmacological and Biomolecular Sciences—Center of Excellence on Neurodegenerative Diseases, University of Milan, Milano, Italy;2. Department of Surgery and Translational Medicine, University of Milan‐Bicocca, Monza, Italy;3. Department of Neurology, S. Gerardo Hospital, Monza, Italy;1. Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 168th St. West, New York, NY, USA, 10032;2. Department of Obstetrics and Gynecology, University of Toronto, 123 Edward St., Suite 1200, Toronto, Ontario, Canada, M5G 1E2 |
| |
Abstract: | OBJECTIVE: To compare severity of negative mood and physical symptoms between women with different progesterone, allopregnanolone, and pregnanolone plasma concentrations during sequential Hormone Replacement Therapy (HRT) with vaginal progesterone suppositories. DESIGN: A randomized, placebo-controlled, double-blind, crossover study. METHOD: Postmenopausal women (n=36) with climacteric symptoms were treated with 2mg estradiol daily during three 28-day cycles. Vaginal progesterone suppositories with 400, 800 mg/day or placebo were added sequentially for 14 days per cycle. Daily symptom ratings using a validated rating scale were kept. Blood samples for progesterone, allopregnanolone, and pregnanolone radioimmunoassays were collected during each treatment cycle. RESULTS: Women were divided into three groups (low, medium, and high) based on plasma allopregnanolone concentration during progesterone treatment. The concentration of allopregnanolone in the medium group corresponds to the concentration seen during the mid luteal phase of the menstrual cycle. Within women with medium allopregnanolone concentration significantly more negative mood and physical symptoms were rated during progesterone treatment compared to treatment with unopposed estrogen or placebo. Between women significantly more negative mood symptoms were seen during progesterone treatment cycles with medium allopregnanolone concentration compared to cycles with low concentration. Plasma progesterone, allopregnanolone, and pregnanolone concentrations increased with increasing progesterone dose. Progesterone and allopregnanolone plasma concentrations increased 2h after vaginal administration of progesterone at 400 and 800 mg/day. CONCLUSION: Vaginal progesterone in sequential HRT causes negative mood, most likely mediated via allopregnanolone. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|